Background: Strategies to improve the life of patients suffering from recurrent major depression have a high relevance. This study examined the efficacy of 2 Internet-delivered augmentation strategies that aim to prolong symptom-free intervals. Methods: Efficacy was tested in a 3-arm, multicenter, open-label, evaluator-blind, randomized controlled trial. Upon discharge from inpatient mental health care, 232 adults with 3 or more major depressive episodes were randomized to 1 of 2 intervention groups (SUMMIT or SUMMIT-PERSON) or to treatment as usual (TAU) alone. Over 12 months, participants in both intervention arms received, in addition to TAU, intense monitoring via e-mail or a smartphone, including signaling of upcoming crises, assistance with personal crisis management, and facilitation of early intervention. SUMMIT-PERSON additionally offered regular expert chats. The primary outcome was ‘well weeks', i.e. weeks with at most mild symptoms assessed by the Longitudinal Interval Follow-Up Evaluation, during 24 months after the index treatment. Results: SUMMIT compared to TAU reduced the time with an unwell status (OR 0.48; 95% CI 0.23-0.98) through faster transitions from unwell to well (OR 1.44; 95% CI 0.83-2.50) and slower transitions from well to unwell (OR 0.69; 95% CI 0.44-1.09). Contrary to the hypothesis, SUMMIT-PERSON was not superior to either SUMMIT (OR 0.77; 95% CI 0.38-1.56) or TAU (OR 0.62; 95% CI 0.31-1.24). The efficacy of SUMMIT was strongest 8 months after the intervention. Conclusions: The fully automated Internet-delivered augmentation strategy SUMMIT has the potential to improve TAU by reducing the lifelong burden of patients with recurrent depression. The fact that the effects wear off suggests a time-unlimited extension.

Keywords:
Internet, Monitoring, Recurrent depression, Efficacy, Disease management
1.
World Health Organization: Strengthening Mental Health Promotion (Fact Sheet No 220). Geneva, World Health Organization, 2001.
2.
Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC: The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:655-679.
3.
ten Doesschate MC, Koeter MWJ, Bockting CLH, Schene AH; DELTA Study Group: Health-related quality of life in recurrent depression: a comparison with a general population sample. J Affect Disord 2010;120:126-132.
4.
Sobocki P, Jönsson B, Angst J, Rehnberg C: Cost of depression in Europe. J Mental Health Policy Econ 2006;9:87-98.
5.
Angst J: Fortnightly review: a regular review of the long-term follow up of depression. BMJ 1997;315:1143-1146.
6.
Frank E, Thase ME: Natural history and preventative treatment of recurrent mood disorders. Annu Rev Med 1999;50:453-468.
7.
Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, Coryell W, Warshaw M, Turvey C, Maser JD, Endicott J: Multiple recurrences of major depressive disorder. Am J Psychiatry 2000;157:329-333.
8.
Hardeveld F, Sijker J, De Graaf R, Nolen WA, Beekman ATF: Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand 2010;122:184-191.
9.
Judd LL, Paulus MJ, Schettler PJ, Akiskal HS, Endicott J, Leon AC, Maser JD, Mueller T, Solomon DA, Keller MB: Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000;157:1501-1504.
10.
Jarrett RB, Kraft D, Doyle J, Foster BM, Eaves GG, Silver PC: Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Arch Gen Psychiatry 2001;58:381-388.
11.
Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093-1099.
12.
Dew MA, White EM, Lenze EJ, Houck PR, Mulsant BH, Pollock BG, Stack JA, Bensasi S, Reynolds CF: Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. Am J Psychiatry 2007;164:892-899.
13.
Keller MB: Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 2003;289:3152-3160.
14.
American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, ed 3. Arlington, American Psychiatric Association, 2010.
15.
Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde; Bundesarbeitsgemeinschaft für psychosoziale Krebsberatungsstellen; Kassenärztliche Bundesvereinigung; Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (eds): Nationale Versorgungsleitlinie: unipolare Depression. Berlin, Springer, 2010.
16.
Frank E, Kupfer DJ, Buysse DJ, Swartz HA, Pilkonis PA, Houck PR, Rucci P, Novick DM, Grochocinski VJ, Stapf DM: Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression. Am J Psychiatry 2007;164:761-767.
17.
Vittengl JR, Clark LA, Dunn TW, Jarrett RB: Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects. J Consult Clin Psychol 2007;75:475-488.
18.
Bockting CL, Hollon SD, Jarrett RB, Kuyken W, Dobson K: A lifetime approach to major depressive disorder: the contribution of psychological interventions in preventing relapse and recurrence. Clin Psychol Rev 2015;41:16-26.
19.
Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam JD, Salomon RM, O'Reardon JP, Lovett ML, Young PR, Haman KL, Freeman BB, Gallop R: Prevention of relapse following cognitive therapy vs. medications in moderate to severe depression. Arch Gen Psychiatry 2005;62:417-422.
20.
Fava GA, Ruini C, Rafanelli C, Finos L, Conti S, Grandi S: Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry 2004;161:1872-1876.
21.
Bockting CL, Schene AH, Spinhoven P, Koeter MW, Wouters LF, Huyser J, Kamphuis JH: Preventing relapse/recurrence in recurrent depression with cognitive therapy: a randomised controlled trial. J Consult Clin Psychol 2005;73:647-657.
22.
Jarrett RB, Minhajuddin A, Gershenfeld H, Friedman ES, Thase ME: Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo. JAMA Psychiatry 2013;70:1152-1160.
23.
Stangier U, Hilling C, Heidenreich T, Risch AK, Barocka A, Schlösser R, Kronfeld K, Ruckes C, Berger H, Röschke J, Weck F, Volk S, Hambrecht M, Serfling R, Erkwoh R, Stirn A, Sobanski T, Hautzinger M: Maintenance cognitive-behavioral therapy and manualized psychoeducation in the treatment of recurrent depression: a multicenter prospective randomized controlled trial. Am J Psychiatry 2013;170:624-632.
24.
Kuyken W, Hayes R, Barrett B, Byng R, Dalgleish T, Kessler D, Lewis G, Watkins E, Brejcha C, Cardy J, Causley A, Cowderoy S, Evans A, Gradinger F, Kaur S, Lanham P, Morant N, Richards J, Shah P, Sutton H, Vicary R, Weaver A, Wilks J, Williams M, Taylor RS, Byford S: Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial. Lancet 2015;386:63-73.
25.
Fava GA, Guidi J, Rafanelli C, Sonino N: The clinical inadequacy of evidence-based medicine and the need for a conceptual framework based on clinical judgement. Psychother Psychosom 2015;84:1-3.
26.
Lavori PW, Dawson R: Adaptive treatment strategies in chronic disease. Annu Rev Med 2008;59:443-453.
27.
Fava GA, Tomba E, Grandi S: A road to recovery from depression - don't drive today with yesterday's map. Psychother Psychosom 2007;76:260-265.
28.
Golkaramnay V, Bauer S, Haug S, Wolf M, Kordy H: The exploration of the effectiveness of group therapy through an Internet chat as aftercare: a controlled naturalistic study. Psychother Psychosom 2007;76:219-225.
29.
Spek V, Cuijpers P, Nyklícek I, Riper H, Keyzer J, Pop V: Internet-based cognitive behavior therapy for symptoms of depression and anxiety: a meta-analysis. Psychol Med 2007;37:319-328.
30.
Mackinnon A, Griffiths KM, Christensen H: Comparative randomised trial of online cognitive-behavioural therapy and an information website for depression: 12-month outcomes. Br J Psychiatry 2008;192:130-134.
31.
Kessler D, Lewis G, Kaur S, Wiles N, King M, Weich S, Sharp DJ, Araya R, Hollinghurst S, Peters TJ: Therapist-delivered Internet psychotherapy for depression in primary care: a randomised controlled trial. Lancet 2009;374:628-634.
32.
Andrews G, Cuijpers P, Craske MG, McEvoy P, Titov N: Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: a meta-analysis. PLoS One 2010;5:e13196.
33.
Andersson G, Cuijpers P: Internet-based and other computerized psychological treatments for adult depression: a meta-analysis. Cogn Behav Ther 2009;38:196-205.
34.
Wiersma JE, Titov N, Van Schaik DJ, Van Oppen P, Beekman AT, Cuijpers P, Andrews GA: Treating chronic symptoms of depression in the virtual clinic: findings on chronicity of depression in patients treated with Internet-based computerized cognitive behaviour therapy for depression. Psychother Psychosom 2011;80:313-315.
35.
Johansson R, Andersson G: Internet-based psychological treatments for depression. Expert Rev Neurother 2012;12:861-869.
36.
Kordy H, Backenstrass M, Hüsing J, Wolf M, Aulich K, Bürgy M, Puschner B, Rummel-Kluge C, Vedder H: Supportive monitoring and disease management through the Internet: an Internet-delivered intervention strategy for recurrent depression. Contemp Clin Trials 2013;36:327-337.
37.
Wittchen H-U, Zaudig M, Fydrich T: SKID: Strukturiertes klinisches Interview für DSM-IV - Achse I und II. Handanweisung. Göttingen, Hogrefe, 1997.
38.
Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott P, Andreasen NC: The Longitudinal Interval Follow-up Evaluation: a comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry 1987;44:540-548.
39.
Spitzer RL, Kroenke K, Williams JB; Patient Health Questionnaire Primary Care Study Group: Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA 1999;282:1737-1744.
40.
Bauer S, Okon E, Meermann R, Kordy H: Technology-enhanced maintenance of treatment outcome in eating disorders: efficacy of an intervention delivered via text messaging. J Consult Clin Psychol 2012;80:700-706.
41.
Andersen PK, Keiding N: Multi-state models for event history analysis. Stat Methods Med Res 2002;11:91-115.
42.
Salazar JC, Schmitt FA, Yu L, Mendiondo MM, Kryscio RJ: Shared random effects analysis of multi-state Markov models: application to a longitudinal study of transitions to dementia. Stat Med 2007;26:568-580.
43.
Kok G, Burger H, Riper H, Cuijpers P, Dekker J, van Marwijk H, Smit F, Beck A, Bockting CLH: The three month effect of mobile Internet-based cognitive therapy on the course of depressive symptoms in remitted recurrently patients: results of a randomised trial. Psychother Psychosom 2015;84:90-99.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.